Published in J Natl Cancer Inst on January 01, 2003
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol (2011) 5.59
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2008) 4.77
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer (2004) 3.03
Cervical cancer prevention: new tools and old barriers. Cancer (2010) 2.68
Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol (2007) 2.27
A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev (2011) 1.82
Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol (2012) 1.78
A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev (2008) 1.53
Preventing cervical cancer globally by acting locally: if not now, when? J Natl Cancer Inst (2010) 1.46
Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol (2009) 1.41
The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies. Int J Cancer (2011) 1.38
Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis (2013) 1.36
Invited commentary: is monitoring of human papillomavirus infection for viral persistence ready for use in cervical cancer screening? Am J Epidemiol (2008) 1.35
Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol (2006) 1.33
Primary care provider practices and beliefs related to cervical cancer screening with the HPV test in Federally Qualified Health Centers. Prev Med (2013) 1.33
HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer (2007) 1.30
A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis (2012) 1.30
Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. J Clin Microbiol (2006) 1.24
Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions. J Clin Microbiol (2007) 1.22
Pilot study of a commercialized human papillomavirus (HPV) genotyping assay: comparison of HPV risk group to cytology and histology. J Clin Microbiol (2006) 1.19
Long-term protective effect of high-risk human papillomavirus testing in population-based cervical screening. Br J Cancer (2005) 1.12
Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. Br J Cancer (2004) 1.08
Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol (2003) 1.05
Role of human papillomaviruses in carcinogenesis. Ecancermedicalscience (2015) 1.00
The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PLoS One (2014) 0.99
Clinical experience with the Cervista HPV HR assay: correlation of cytology and HPV status from 56,501 specimens. J Mol Diagn (2011) 0.98
HPV testing by cobas HPV test in a population from Catalonia. PLoS One (2013) 0.92
The Peru Cervical Cancer Prevention Study (PERCAPS): the technology to make screening accessible. Gynecol Oncol (2013) 0.92
Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women. BMC Cancer (2010) 0.92
Comparison between the Hybrid Capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol (2005) 0.90
Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. Int J Cancer (2009) 0.90
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer (2008) 0.89
Population-based study of human papillomavirus infection and cervical neoplasia in Athens, Greece. Epidemiol Infect (2007) 0.88
Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role. Cancer (2008) 0.87
Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic. BMC Infect Dis (2010) 0.86
HPV genotype distribution according to severity of cervical neoplasia using the Digene HPV genotyping LQ test. Arch Virol (2013) 0.86
Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice. Gynecol Oncol (2011) 0.86
Barriers to adoption of recent technology in cervical screening. Cytojournal (2007) 0.85
Human papillomavirus testing in cervical cancer screening. Br J Cancer (2005) 0.84
Distribution of high-risk human papillomavirus genotypes among HIV-negative women with and without cervical intraepithelial neoplasia in South Africa. PLoS One (2012) 0.84
Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland. Br J Cancer (2013) 0.83
Evaluation of any or type-specific persistence of high-risk human papillomavirus for detecting cervical precancer. J Clin Microbiol (2011) 0.83
Evaluation of the detection of 14 high-risk human papillomaviruses with HPV 16 and HPV 18 genotyping for cervical cancer screening. Exp Ther Med (2013) 0.83
Comparison of the accuracy of Hybrid Capture II and polymerase chain reaction in detecting clinically important cervical dysplasia: a systematic review and meta-analysis. Cancer Med (2013) 0.82
Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing. Br J Cancer (2012) 0.81
The distribution of high-risk human papillomaviruses is different in young and old patients with cervical cancer. PLoS One (2014) 0.81
HPV DNA testing improves CIN2+ risk stratification and detection of CIN2+ in delayed triage of ASCUS and LSIL. A population-based follow-up study from Western Norway. Cancer Med (2013) 0.80
Laboratory and clinical aspects of human papillomavirus testing. Crit Rev Clin Lab Sci (2012) 0.80
New strategies for human papillomavirus-based cervical screening. Womens Health (Lond Engl) (2013) 0.80
Asia oceania guidelines for the implementation of programs for cervical cancer prevention and control. J Cancer Epidemiol (2011) 0.80
Long-term outcomes of high-risk human papillomavirus infection support a long interval of cervical cancer screening. Br J Cancer (2008) 0.80
HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice. Ecancermedicalscience (2012) 0.79
Cervical cancer screening and follow-up in 4 geographically diverse US health care systems, 1998 through 2007. Cancer (2015) 0.78
Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy. Int J Cancer (2011) 0.78
Quantitative screening of single copies of human papilloma viral DNA without amplification. Anal Chem (2006) 0.77
Evaluation of a novel real-time fluorescent polymerase chain reaction assay for high-risk human papilloma virus DNA genotypes in cytological cervical screening. Biomed Rep (2012) 0.77
Prevalence and clinical utility of human papilloma virus genotyping in patients with cervical lesions. J Obstet Gynaecol India (2014) 0.76
Comparison of the performance of carcinogenic HPV typing of the Roche Linear Array and Qiagen LiquiChip® HPV assays. BMC Infect Dis (2013) 0.76
Evaluation of careHPV, Cervista Human Papillomavirus, and Hybrid Capture 2 Methods in Diagnosing Cervical Intraepithelial Neoplasia Grade 2+ in Xinjiang Uyghur Women. Oncologist (2016) 0.75
Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study. BMJ Open (2016) 0.75
Assessment of the performance of algorithms for cervical cancer screening: evidence from the Ludwig-McGill cohort study. Gynecol Oncol (2012) 0.75
Hybrid capture II for high-risk human papillomavirus DNA testing to detect cervical precancerous lesions: A qualitative and quantitative study. Exp Ther Med (2010) 0.75
Cost is a barrier to widespread use of liquid-based cytology for cervical cancer screening in Korea. J Korean Med Sci (2006) 0.75
Hybrid Capture 2 is as effective as PCR testing for high-risk human papillomavirus in head and neck cancers. Appl Immunohistochem Mol Morphol (2015) 0.75
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Replicating genotype-phenotype associations. Nature (2007) 16.11
Human papillomavirus and cervical cancer. Lancet (2007) 12.47
Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet (2010) 9.07
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol (2011) 5.59
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
The Diesel Exhaust in Miners study: a nested case-control study of lung cancer and diesel exhaust. J Natl Cancer Inst (2012) 5.27
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet (2005) 5.01
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
The carcinogenicity of human papillomavirus types reflects viral evolution. Virology (2005) 4.72
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA (2007) 4.66
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol (2008) 4.43
Powerful multilocus tests of genetic association in the presence of gene-gene and gene-environment interactions. Am J Hum Genet (2006) 4.40
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol (2006) 4.13
Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst (2010) 3.95
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology (2004) 3.85
Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis (2005) 3.84
Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst (2009) 3.77
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol (2004) 3.67
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer (2009) 3.64
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis (2007) 3.59
Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol (2002) 3.53
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis (2005) 3.46
Population substructure and control selection in genome-wide association studies. PLoS One (2008) 3.44
Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis (2011) 3.44
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst (2008) 3.32
Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine (2008) 3.17
Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer (2009) 3.15
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol (2006) 3.08
A new statistic and its power to infer membership in a genome-wide association study using genotype frequencies. Nat Genet (2009) 3.06
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
Beyond odds ratios--communicating disease risk based on genetic profiles. Nat Rev Genet (2009) 3.01
The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol (2007) 2.91
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst (2010) 2.81
Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol (2009) 2.74
Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol (2003) 2.71
Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ (2009) 2.68
Cervical cancer prevention: new tools and old barriers. Cancer (2010) 2.68
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov (2011) 2.66
Special commentary: patient safety and the next generation of HPV DNA tests. Am J Clin Pathol (2010) 2.65
Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol (2010) 2.61
A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst (2005) 2.60
Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol (2002) 2.56
The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol (2007) 2.52
Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol (2008) 2.51
Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine (2006) 2.51
Interpreting epidemiologic research: lessons from studies of childhood cancer. Pediatrics (2003) 2.49
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood (2008) 2.49
Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst (2005) 2.47
Impact of occupational carcinogens on lung cancer risk in a general population. Int J Epidemiol (2012) 2.46
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet (2008) 2.45